

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Proposed Single Technology Appraisals

1. Nivolumab for treating advanced, unresectable melanoma after progression with anti-CTLA-4 therapy ID 845
2. Nivolumab for untreated advanced, unresectable melanoma without a BRAF mutation ID 846
3. Nivolumab for untreated advanced, unresectable BRAF V600 mutation-positive melanoma ID 847
4. Nivolumab in combination with ipilimumab for untreated advanced, unresectable melanoma ID 848

## Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Bristol-Myers Squibb (nivolumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• British Skin Foundation</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer 52</li> <li>• Equalities National Council</li> <li>• HAWC</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Melanoma UK</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• OcuMel UK</li> <li>• Rarer Cancers Foundation</li> <li>• Skcin - Karen Clifford Skin Cancer Charity</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Anaesthetists</li> <li>• Association of Cancer Physicians</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Bayer (dacarbazine)</li> <li>• Bristol-Myers Squibb (ipilimumab)</li> <li>• GlaxoSmithKline (dabrafenib)</li> <li>• Hospira UK (dacarbazine)</li> <li>• medac UK (dacarbazine)</li> <li>• Roche Products (vemurafenib)</li> <li>• Teva UK (dacarbazine)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Society for Dermatological Surgery</li> <li>• Cochrane Skin Group</li> </ul>

National Institute for Health and Care Excellence

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association of Dermatologists</li> <li>• British Association of Skin Cancer Specialist Nurses</li> <li>• British Association of Surgical Oncology</li> <li>• British Dermatological Nursing Group</li> <li>• British Geriatrics Society</li> <li>• British Institute of Radiology</li> <li>• British Psychosocial Oncology Society</li> <li>• Cancer Research UK</li> <li>• Melanoma Focus</li> <li>• Primary Care Dermatology Society</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Health Forum</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Bury CCG</li> <li>• NHS Calderdale CCG</li> <li>• NHS Croydon CCG</li> <li>• NHS England</li> <li>• NHS Great Yarmouth &amp; Waveney CCG</li> <li>• NHS Hounslow CCG</li> <li>• NHS Luton CCG</li> <li>• NHS North Derbyshire CCG</li> <li>• NHS Wakefield CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• Myfanwy Townsend Melanoma Research Fund</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Skin Cancer Research Fund</li> <li>• Skin Research Centre</li> <li>• Skin Treatment &amp; Research Trust</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and

those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that manufacture comparator technologies; Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.